Abstract
Gain of chromosome 17q material is the most frequent genetic abnormality in neuroblastomas. The common region of gain is at least 375 cR large, which has precluded the identification of genes with a role in neuroblastoma pathogenesis. Neuroblastoma also frequently show amplification of the N-myc oncogene, which correlates closely with 17q gain. Both events are strong predictors of unfavorable prognosis. To identify genes that are part of the N-myc downstream pathway, we constructed SAGE libraries of an N-myc transfected and a control cell line. This identified the chromosome 17q genes nm23-H1 and nm23-H2 as being 6–10 times induced in the N-myc expressing cells. Northern and Western blot analysis confirmed this up-regulation. Time-course experiment shows that both genes are induced within 4 h after N-myc is switched on. Furthermore, we demonstrate also that c-myc can up-regulate nm23-H1 and nm23-H2 expression. Neuroblastoma tumor and cell line panels reveal a striking correlation between N-myc amplification and mRNA and protein expression of both nm23 genes. We show that the nm23 genes are located at the edge of the common region of chromosome 17q gain previously described in neuroblastoma cell lines. Our findings suggest that nm23-H1 and nm23-H2 expression is increased by 17q gain in neuroblastoma and can be further up-regulated by myc overexpression. These observations suggest a major role for nm23-H1 and nm23-H2 in tumorigenesis of unfavorable neuroblastomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Backer JM, Mendola CE, Kovesdi I, Fairhurst JL, O'Hara B, Eddy Jr RL, Shows TB, Mathew S, Murty VV, Chaganti RS . 1993 Oncogene 8: 497–502
Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, Van Sluis P, Roobeek I, Weis I, Voute PA, Schwab M, Versteeg R . 2001 EMBO J. 20: 1383–1393
Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Speleman F . 1999 N. Engl. J. Med. 340: 1954–1961
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM . 1984 Science 224: 1121–1124
Caron H . 1995 Med. Pediatr. Oncol. 24: 215–221
Cheng NC, Beitsma M, Chan A, Op dC I, Westerveld A, Pronk J, Versteeg R . 1996 Oncogene 13: 1737–1744
Florenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O . 1992 Cancer Res. 52: 6088–6091
Lastowska M, Van Roy N, Bown N, Speleman F, Lunec J, Strachan T, Pearson AD, Jackson MS . 1998 Genes Chromosomes. Cancer 23: 116–122
Lombardi D, Lacombe ML, Paggi MG . 2000 J. Cell Physiol 182: 144–149
Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M . 1996 Oncogene 13: 803–812
Malynn BA, de Alboran IM, O'Hagan RC, Bronson R, Davidson L, DePinho RA, Alt FW . 2000 Genes Dev. 14: 1390–1399
Meddeb M, Danglot G, Chudoba I, Venuat AM, Benard J, Avet-Loiseau H, Vasseur B, Le Paslier D, Terrier-Lacombe MJ, Hartmann O, Bernheim A . 1996 Genes Chromosomes. Cancer 17: 156–165
Niitsu N, Okabe-Kado J, Okamoto M, Takagi T, Yoshida T, Aoki S, Hirano M, Honma Y . 2001 Blood 97: 1202–1210
Pinon VP, Millot G, Munier A, Vassy J, Linares-Cruz G, Capeau J, Calvo F, Lacombe ML . 1999 Exp. Cell Res. 246: 355–367
Schuhmacher M, Kohlhuber F, Holzel M, Kaiser C, Burtscher H, Jarsch M, Bornkamm GW, Laux G, Polack A, Weidle UH, Eick D . 2001 Nucleic Acids Res. 29: 397–406
Van Roy N, Cheng NC, Laureys G, Opdenakker G, Versteeg R, Speleman F . 1995 Eur. J. Cancer 31A: 530–535
Versteeg R, Noordermeer IA, Kruse-Wolters M, Ruiter DJ, Schrier PI . 1988 EMBO J. 7: 1023–1029
Acknowledgements
We thank ML Lacombe for providing the NM23-H1 and H2 antibodies. This research was supported by grants from the Dutch Cancer Society (AMC97-1461), the Stichting Kindergeneeskundig Kankeronderzoek. HN Caron is a research fellow of The Royal Netherlands Academy of Arts and Sciences (KNAW).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Godfried, M., Veenstra, M., v Sluis, P. et al. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2. Oncogene 21, 2097–2101 (2002). https://doi.org/10.1038/sj.onc.1205259
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205259
Keywords
This article is cited by
-
NDPKA is not just a metastasis suppressor – be aware of its metastasis-promoting role in neuroblastoma
Laboratory Investigation (2018)
-
Oncogenic Epstein–Barr virus recruits Nm23-H1 to regulate chromatin modifiers
Laboratory Investigation (2018)
-
Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction
Scientific Reports (2013)
-
Mechanisms of non-metastatic 2 (NME2)-mediated control of metastasis across tumor types
Naunyn-Schmiedeberg's Archives of Pharmacology (2011)
-
Aggregation of the neuroblastoma-associated mutant (S120G) of the human nucleoside diphosphate kinase-A/NM23-H1 into amyloid fibrils
Naunyn-Schmiedeberg's Archives of Pharmacology (2011)